Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity
Journal for ImmunoTherapy of Cancer · 2026-07 · 14 (7) · e015090
DOI: 10.1136/jitc-2026-015090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 14.07.2026. Verfasst von Nicole Oelgarth und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Interleukin-18, Programmed Cell Death 1 Receptor, Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss Cancer League, H2020 Marie Skłodowska-Curie Actions, Bright Peak Therapeutics.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors have revolutionized cancer therapy, yet a substantial proportion of patients exhibit primary or acquired resistance. Immunocytokines offer a strategy to enhance antitumor immunity by delivering cytokine signals selectively to the tumor microenvironment. Here, we describe the immunoconjugate anti-programmed cell death protein 1 (PD-1)-interleukin (IL)-18 (aPD1-IL18 mut ), designed to couple PD-1-blockade with localized IL-18-mediated immune activation. Methods aPD1-IL18 mut was generated by chemically conjugating the anti-human PD-1 antibody Lipustobart to an IL-18 variant engineered to evade IL-18 binding protein. Its mechanism of action was characterized using human PD-1 transgenic mouse models. To assess the translational relevance of these in vivo findings, complementary in vitro assays were conducted on human tumor samples, alongside analyses of publicly available single-cell RNA sequencing datasets.
Results
In vitro, PD-1 engagement enhanced functional IL-18 activity, preserving interferon (IFN)-γ secretion even under IL-18BP pressure. In MC38 tumors, aPD1-IL18 mut induced robust CD8 + T cell-driven tumor control, accompanied by intratumoral accumulation of activated CD8 + T cells and a pronounced type 1-associated cytokine response. In anti-PD-1-resistant YUMM1.7 tumors, therapeutic efficacy instead relied predominantly on Th1-like CD4 + effector T cells, and aPD1-IL18 mut stimulation was associated with enhanced activation, proliferation, IFN-γ, and granzyme B expression in PD-1 + IL-18Rɑ + CD4 + T cells. In human cancer digest cultures, aPD1-IL18 mut elicited a dominant IL-18/IFN-γ-driven cytokine signature and enhanced tumor cell killing. Importantly, analyses of the immune infiltrate across multiple human solid tumor types identified analogous PD-1 + IL-18Rɑ + CD4 + Th1-like and CD8 + effector-like T-cell subsets with effector-associated and tumor-reactive transcriptional and protein signatures. Conclusions aPD1-IL18 mut activates T-cell populations with tumor-reactive features and promotes IFN-γ-driven inflammation across distinct tumor immune contexts. Its ability to activate CD8 + and CD4 + Th1-like effector cells, together with the presence of analogous subsets in multiple human cancers, provides mechanistic and translational support for PD-1-targeted IL-18 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
- Bright Peak Therapeutics, Allschwil, Switzerland.
- Department of Gynecology and Obstetrics, University Hospital Basel, Basel, Switzerland.
- Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
- Department of Visceral Surgery, Cantonal Hospital Basel-Landschaft, Liestal, Switzerland.
- Bright Peak Therapeutics, Allschwil, Switzerland alfred.zippelius@usb.ch vpattabiraman@brightpeaktx.com.
Förderung
- Swiss Cancer League
- H2020 Marie Skłodowska-Curie Actions
- Bright Peak Therapeutics
Zitieren
APA
Oelgarth, N., Martin, K., Junker, F., Serger, C., Herr, C., Buchi, M., Gremlich, L., Fusi, I., Fürst, J., Herzig, P., Moosmann, P., Heinzelmann-Schwarz, V., Mertz, K. D., Rosenberg, R., Schaeuble, K., Carralot, J. P., Luu, T. T., Kreft, B., Pattabiraman, V., & Zippelius, A. (2026). Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity. Journal for ImmunoTherapy of Cancer, 14(7), e015090. https://doi.org/10.1136/jitc-2026-015090
Vancouver
Oelgarth N, Martin K, Junker F, Serger C, Herr C, Buchi M, et al. Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity. Journal for ImmunoTherapy of Cancer. 2026;14(7):e015090. doi:10.1136/jitc-2026-015090
BibTeX
@article{Oelgarth2026,
author = {Oelgarth, Nicole and Martin, Kea and Junker, Fabian and Serger, Clara and Herr, Caoimhe and Buchi, Mélanie and Gremlich, Lilian and Fusi, Irene and Fürst, Jonas and Herzig, Petra and Moosmann, Philipp and Heinzelmann-Schwarz, Viola and Mertz, Kirsten D and Rosenberg, Robert and Schaeuble, Karin and Carralot, Jean-Philippe and Luu, Thuy T and Kreft, Bertolt and Pattabiraman, Vijaya and Zippelius, Alfred},
title = {Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {7},
pages = {e015090},
doi = {10.1136/jitc-2026-015090}
}
EUVIMED